Alterity Therapeutics (ASX:ATH) has announced that its Phase 2 trial of ATH434 for treating patients with Multiple System Atrophy is now open for enrollment in Italy. …
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 Australian Biotech
Latest Video
New Stories
-
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast -
Another day, another confusing response to the threat of US tariffs
July 17, 2025 - - Latest News -
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News